XML 11 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 117,975 $ 50,482
Accounts receivable, net 121 481
Inventories 3,864 3,155
Prepaid expenses and other current assets 11,463 31,542
Current assets held for sale 0 110,849
Total current assets 133,423 196,509
Long-term investments 3,035 0
Other assets 556 1,405
Long-term assets held for sale 0 16,611
Total assets 137,014 214,525
Current liabilities:    
Accounts payable 5,093 5,064
Accrued and other current liabilities 25,776 62,035
Deferred revenue 5,104 27,290
Current liabilities held for sale 0 38,917
Total current liabilities 35,973 133,306
Product development obligations 19,471 17,012
Deferred revenue, net of current 573 114,708
Senior secured term loan facilities, non-current 0 73,092
Liability related to sale of future revenues, non-current 63,414 58,864
Other long-term liabilities 98 822
Long-term liabilities held for sale 0 356
Total liabilities 119,529 398,160
Commitments and Contingencies
Redeemable non-controlling interests 21,480 21,480
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at September 30, 2025 and December 31, 2024
Common stock, $0.01 par value; 225,000 shares authorized at September 30, 2025 and December 31, 2024; 4,045 and 4,037 shares issued and outstanding at September 30, 2025 and December 31, 2024 1,011 1,009
Additional paid-in capital 1,675,999 1,668,620
Accumulated other comprehensive loss (2,211) (5,732)
Accumulated deficit (1,691,827) (1,889,499)
Total stockholders' deficit attributable to FibroGen (17,028) (225,602)
Nonredeemable non-controlling interests 13,033 20,487
Total deficit (3,995) (205,115)
Total liabilities, redeemable non-controlling interests and deficit $ 137,014 $ 214,525